This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Otsuka Holdings Co., Ltd.

Drug Names(s): AVP-13358

Description: AVP 13358 is intended to inhibit the production of IgE antibodies. In addition to its effect on IgE, this compound has demonstrated an ability to suppress the antigen-stimulated IL-4 and IL-5responses with potencies similar to those observed for IgE suppression. AVP 13358 also suppresses markers of disease in mouse models of asthma, including pulmonary lavage levels of IL-4, IL-5, eosinophils, and lymphocytes, as wellas expression of CD23 and the IL-4 receptor (IL-4Ralpha) on leukocytes. AVP 13358 is orally active and appears to be selective for the suppression of Th2 cytokine-mediated diseases.

Deal Structure: Avanir and Otsuka
In December 2014, Avanir entered into a definitive agreement with Otsuka pursuant to which Otsuka will acquire Avanir for $17.00 per share in cash. The transaction, which values Avanir at approximately $3.5 billion, has been unanimously approved by the boards of directors of both companies.

In January 2015, Otsuka announced that it has successfully completed its acquisition of Avanir.

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug